References
- Schiedler V, Scott IU, Flynn HW, Jr, Davis JL, Benz MS, Miller D. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol 2004; 137: 725–31
- Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous endophthalmitis: an 18-y review of culture-positive cases at a tertiary care centre. Medicine (Baltimore) 2003; 82: 97–105
- Leibovitch I, Tze Lai, Raymond G, Zadeh R, Nathan F, Selva D. Endogenous endophthalmitis: a 13-y review in a tertiary hospital in south Australia. Scand J Infect Dis 2005; 37: 184–9
- Bisbe J, Miro JM, Latore X, Moreno A, Mallolas J, Gatell JM, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15: 910–23
- Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidaemia. Clinical implications derived from a prospective multicentre study. Ophthalmology 1994; 101: 1302–9
- Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev 2000; 13: 662–85
- Schmid S, Martenet AC, Oelz O. Candida endophthalmitis: clinical presentation, treatment and outcome in 23 patients. Infection 1991; 19: 21–4
- Edwards JE, Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicaemia: review of 76 cases of haematogenous Candida endophthalmitis. Medicine (Baltimore) 1974; 53: 47–75
- Dupont B, Drouhet E. Cutaneous, ocular, and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients. J Infect Dis 1985; 152: 577–91
- Shankland GS, Richardson MD, Dutton GN. Source of infection in Candida endophthalmitis in drug addicts. Br Med J 1986; 292: 1106–7
- Ministerio de Sanidad y Consumo. Plan Nacional Sobre Drogas. Observatorio Español sobre Drogas (OED). ( http://www.msc.es/pnd/observa/pdf/02_F_2002.ppt)
- Tanaka M, Kobayashi Y, Takebayashi H, Kiyokawa M, Qiu H. Analyis of predisposing clinical and laboratory findings for the development of endogenous fungal endophthalmitis. A retrospective 12-y study of 79 eyes of 46 patients. Retina 2001; 21: 203–9
- Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidaemia: results from a 20-y nationwide study in Iceland. J Clin Microbiol 2002; 40: 3489–92
- Alonso-Valle H, Acha O, Garcia-Palomo JD, Farinas-Alvarez C, Fernandez-Mazarrasa C, Farinas MC. Candidaemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254–7
- Fisher JE. Penetration of amphotericin B into the human eye. J Infect Dis 1983; 147: 164–5
- Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987; 31: 6–10
- Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002; 46: 3719–23
- Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–89
- Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139: 135–40
- Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, Prince RA. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122: 42–7
- Darling K, Singh J, Wilks D. Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC). J Infect 2000; 40: 92–4
- Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40: 46–8
- Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41: 27–8
- Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45: 3322–7
- Takebayashi, H, Mizota, A, Tanaka, M. Relation between stage of endogenous fungal endophthalmitis and prognosis. Graefes Arch Clin Exp Ophthalmol 2006;244: 816–20.
- Martínez-Vázquez C, Fernández-Ulloa J, Bordón J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998; 27: 1130–3